Recursion Pharmaceuticals (RXRX) Depreciation & Amortization (CF) (2020 - 2026)

Recursion Pharmaceuticals has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $19.7 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 1.77% year-over-year to $19.7 million; the trailing twelve-month figure through Mar 2026 stood at $84.0 million (up 73.47% YoY), and the FY2025 full-year result was $83.7 million, up 129.36% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $19.7 million, up from $19.5 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $23.8 million in Q2 2025, with the low at $2.8 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $10.4 million across 5 years, with a median of $7.6 million in 2023.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) fell 5.01% — and 2025, when it jumped 192.35%.
• Recursion Pharmaceuticals' Depreciation & Amortization (CF) stood at $3.2 million in 2022, then surged by 135.0% to $7.6 million in 2023, then surged by 71.47% to $13.0 million in 2024, then soared by 50.4% to $19.5 million in 2025, then rose by 1.0% to $19.7 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $19.7 million (Q1 2026), $19.5 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.